Zai Lab (9688 HK)

Analysis

Health Care • China

Zai Lab is an innovative, research-based, commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative products for oncology, immunology, neuroscience, and infectious diseases. The company has commercialized products such as Zejula, Optune, Qinlock, Nuzyra, and Vyvgart in China. Zai Lab was founded in 2014 and is headquartered in Shanghai, China, and Cambridge, Massachusetts, USA.

Refresh

Exchange Announcement • 11 Sep 2026 18:10

Grant Of Restricted Share Units

Exchange Announcement • 28 Aug 2026 18:14

2026 Interim Report

Exchange Announcement • 26 Aug 2026 06:27

Interim Results Announcement For The Six Months Ended June 30, 2026

Exchange Announcement • 13 Aug 2026 17:03

Notice Of Audit Committee Action

Exchange Announcement • 11 Aug 2026 21:53

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Grant Of Restricted Share Units

2026 Interim Report

Interim Results Announcement For The Six Months Ended June 30, 2026

Notice Of Audit Committee Action

Grant Of Share Options And Restricted Share Units